Copperleaf Technologies has been selected by Abbott Products Operations AG to enhance its investment planning process.
Abbott, a global healthcare leader, is moving from a manual and reactive approach to a streamlined process that considers long-term strategic planning using Copperleaf Portfolio.
The solution will provide Abbott with data-driven insights into the condition and recapitalisation priority of its capital and production assets, improving investment decision-making by leveraging a clear understanding of the associated risks and benefits.
The solution will allow Abbott to achieve a balanced and optimised allocation of capital expenditure across its sites by creating the highest-value investment strategies that respect targets and resource constraints.
Copperleaf’s solution will enable Abbott to make better and more consistent investment decisions based on an efficient and streamlined investment planning process. The solution will also allow Abbott to assess and compare investments on a common economic scale to ensure that resources are allocated in the best possible way to meet strategic goals.
Stefan Sadnicki, Managing Director for Copperleaf in Europe, Middle East, and Africa (EMEA) welcomed Abbott to the Copperleaf Community as the company’s first client in the pharmaceutical industry.
The announcement is expected to improve the investment planning process of Abbott, which is considered an important project.
Copperleaf Portfolio will allow Abbott to make better and more consistent investment decisions by providing data-driven insights into the condition and recapitalisation priority of its capital and production assets, enabling it to assess and compare investments on a common economic scale to ensure the best possible allocation of resources.
